UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

~~The~~the Securities Exchange Act of 1934

~~Date~~July of1, ~~Report (Date of earliest event reported)~~2010

Date of Report (date of earliest event reported)

SENORX, INC.

(Exact name of ~~registrant~~Registrant as specified in its charter)

Delaware	001-33382	~~001~~33-~~33382~~0787406	~~33-0787406~~
(State or other jurisdiction of incorporation)		(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)

3 Morgan, Irvine, California 92618

~~Irvine,~~(Address ~~California~~of ~~92618~~principal executive offices)

(Address of principal executive offices, including zip code)

(949) 362-4800

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ _] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ _] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ _] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ _] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 85.0107. Submission ~~Other~~of ~~Events~~Matters to a Vote of Security Holders.

OnA ~~June 17,~~special ~~2010~~meeting ~~the Federal Trade Commission granted early termination~~ of ~~the~~stockholders ~~waiting period under the Hart-Scott-Rodino Antitrust Improvements Act~~ of ~~1976~~SenoRx, ~~as amended, relating to the pending acquisition by C. R. Bard,~~ Inc. (“~~Bard”) of~~ SenoRx~~, Inc. (“SenoRx~~”). ~~The~~was ~~proposed~~held ~~merger~~at ~~remains~~9:00 ~~subject~~a.m. tolocal ~~other~~time ~~customary~~on ~~closing~~July ~~conditions~~1, ~~including~~2010, ~~the~~at ~~approval of~~ SenoRx’s ~~stockholders. The~~corporate ~~special~~headquarters ~~meeting~~at of3 ~~SenoRx’s stockholders to vote on the proposed merger is currently scheduled to be held on Thursday~~Morgan, ~~July 1~~Irvine, ~~2010~~California 92618-1917.

~~Additional~~The ~~Information~~issued and ~~Where~~outstanding shares of stock of SenoRx entitled to ~~Find~~vote Itat the special meeting consisted of 17,642,048 shares of common stock. The stockholders of SenoRx voted on two matters at the special meeting, both of which were approved pursuant to the following final voting results from the special meeting:

~~In connection with the proposed merger, SenoRx filed a definitive proxy statement on June 4, 2010 with the Securities and Exchange Commission~~ (~~“SEC”~~1)~~. On~~ A orproposal ~~about~~to ~~June~~adopt ~~7, 2010, SenoRx began mailing~~ the ~~definitive~~Agreement ~~proxy~~and ~~statement~~Plan ~~to SenoRx stockholders~~ of ~~record~~Merger, dated as of ~~the~~May ~~close of business on June 1~~4, 2010., ~~SenoRx~~as ~~has~~it ~~also~~may ~~filed,~~be ~~and~~amended ~~intends~~from totime ~~continue~~ to ~~file~~time, ~~additional~~among ~~relevant materials with the SEC~~C. ~~INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS FILED WITH THE SEC CAREFULLY~~R. ~~Investors~~Bard, ~~and stockholders may obtain free copies of the proxy statement and other documents filed with the SEC by SenoRx through the Web site maintained by the SEC at www~~Inc.~~sec.gov. In addition~~, ~~investors~~a ~~and~~New ~~stockholders~~Jersey ~~may~~corporation ~~obtain free copies of the proxy statement from SenoRx by contacting Investor Relations by telephone at +1~~ (~~949~~“Bard”) ~~362-4800 ext. 132~~, byRaptor ~~mail~~Acquisition ~~at SenoRx, Inc~~Corp., 3a ~~Morgan,~~Delaware ~~Irvine,~~corporation ~~California,~~and ~~92618,~~indirect ~~Attn:~~wholly ~~Investor~~owned ~~Relations,~~subsidiary byof ~~e-mail~~Bard, atand ~~lchurney@senorx.com~~SenoRx, orpursuant ~~by going~~ to which SenoRx’s ~~Investor~~will ~~Relations~~be ~~page~~acquired onby ~~its corporate Web site at www~~Bard.~~senorx.com (click on “Investors,” then on “SEC Filings”).~~

SenoRx and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of SenoRx in connection with the proposed merger. Information regarding the interests of these directors and executive officers in the transaction described is included in the proxy statement described above. Additional information regarding these directors and executive officers is also included in SenoRx’s proxy statement for its 2010 Annual Meeting of Stockholders, which was filed with the SEC on April 30, 2010. This document is available free of charge at the SEC’s Web site at www.sec.gov, and from SenoRx by contacting Investor Relations by telephone at +1 (949) 362-4800 x132, by mail at SenoRx, Inc., 3 Morgan, Irvine, California, 92618, Attn: Investor Relations, by e-mail at lchurney@senorx.com, or by going to SenoRx’s Investor Relations page on its corporate Web site at www.senorx.com (click on “Investors,” then on “SEC Filings”).

FOR		AGAINST		ABSTAIN
14,935,350		20,500		6,522

(2) A proposal to adjourn the special meeting to a later date or time, if necessary or appropriate, to solicit additional proxies in the event there are insufficient votes at the time of such adjournment to adopt the Agreement and Plan of Merger.

FOR		AGAINST		ABSTAIN
14,832,347		123,203		6,822

SenoRx expects to close the merger with Bard on or about July 6, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SENORX, INC. By: /s/ Kevin J. Cousins Name: Kevin J. Cousins Title: Chief Financial Officer, Vice President, Finance

	SENORX, INC.

Date: July 1, 2010	By:	/s/ Kevin J. Cousins
		Kevin J. Cousins
		Chief Financial Officer, Vice President, Finance

Date: June 18, 2010

Filing Compare · SENORX INC